{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:31:51Z","timestamp":1788258711674,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000304","name":"Parkinson&apos;s UK","doi-asserted-by":"publisher","award":["G1604"],"award-info":[{"award-number":["G1604"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson&apos;s UK","doi-asserted-by":"publisher","award":["G1604"],"award-info":[{"award-number":["G1604"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson&apos;s UK","doi-asserted-by":"publisher","award":["G1604"],"award-info":[{"award-number":["G1604"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Endogenous fibroblast growth factor 20 (FGF20) supports maintenance of dopaminergic neurones within the nigrostriatal pathway. Moreover, direct intracerebral infusion of FGF20 protects against nigrostriatal tract loss in the 6-hydroxydopamine lesion rat model of Parkinson\u2019s disease. Increasing endogenous FGF20 production might provide a less-invasive, more translational way of providing such protection. Accordingly, we adopted a <jats:italic>targeted repositioning<\/jats:italic> approach to screen for candidate FDA-approved drugs with potential to enhance endogenous FGF20 production in brain. <jats:italic>In silico<\/jats:italic> interrogation of the Broad Institute\u2019s Connectivity Map database (CMap), revealed 50 candidate drugs predicted to increase FGF20 transcription, 16 of which had profiles favourable for use in Parkinson\u2019s disease. Of these, 11 drugs were found to significantly elevate FGF20 protein production in MCF-7 cells, between two- and four-fold. Four drugs were selected for examination <jats:italic>in vivo<\/jats:italic>. Following oral dosing in rats for 7 days, salbutamol and triflusal, but not dimethadione or trazodone, significantly elevated FGF20 levels in the nigrostriatal tract. Preliminary examination in the unilateral 6-hydroxydopamine-lesioned rat revealed a modest but significant protection against nigral cell loss with both drugs. Our data demonstrate the power of <jats:italic>targeted repositioning<\/jats:italic> as a method to identify existing drugs that may combat disease progression in Parkinson\u2019s by boosting FGF20 levels.<\/jats:p>","DOI":"10.1038\/s41598-019-44803-1","type":"journal-article","created":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T10:03:09Z","timestamp":1559815389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats"],"prefix":"10.1038","volume":"9","author":[{"given":"Edward J. R.","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aran D.","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3408-5973","authenticated-orcid":false,"given":"Susan","family":"Duty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"key":"44803_CR1","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees, A. J., Hardy, J. & Revesz, T. Parkinson\u2019s disease. Lancet 373, 2055\u20132066, https:\/\/doi.org\/10.1016\/S0140-6736(09)60492-X (2009).","journal-title":"Lancet"},{"key":"44803_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","volume":"11","author":"A AlDakheel","year":"2014","unstructured":"AlDakheel, A., Kalia, L. V. & Lang, A. E. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 11, 6\u201323, https:\/\/doi.org\/10.1007\/s13311-013-0218-1 (2014).","journal-title":"Neurotherapeutics"},{"key":"44803_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00702-016-1667-6","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova, N., Padmakumar, C., Lewis, S. J. G. & Chaudhuri, K. R. Parkinson\u2019s: a syndrome rather than a disease? J Neural Transm (Vienna) 124, 907\u2013914, https:\/\/doi.org\/10.1007\/s00702-016-1667-6 (2017).","journal-title":"J Neural Transm (Vienna)"},{"key":"44803_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1006\/bbrc.2000.3675","volume":"277","author":"S Ohmachi","year":"2000","unstructured":"Ohmachi, S. et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem Biophys Res Commun 277, 355\u2013360, https:\/\/doi.org\/10.1006\/bbrc.2000.3675 (2000).","journal-title":"Biochem Biophys Res Commun"},{"key":"44803_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.nbd.2004.07.007","volume":"17","author":"C Grothe","year":"2004","unstructured":"Grothe, C. et al. Fibroblast growth factor-20 promotes the differentiation of Nurr1-overexpressing neural stem cells into tyrosine hydroxylase-positive neurons. Neurobiol Dis 17, 163\u2013170, https:\/\/doi.org\/10.1016\/j.nbd.2004.07.007 (2004).","journal-title":"Neurobiol Dis"},{"key":"44803_CR6","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.neuropharm.2012.07.029","volume":"63","author":"IJ Sleeman","year":"2012","unstructured":"Sleeman, I. J., Boshoff, E. L. & Duty, S. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease. Neuropharmacology 63, 1268\u20131277, https:\/\/doi.org\/10.1016\/j.neuropharm.2012.07.029 (2012).","journal-title":"Neuropharmacology"},{"key":"44803_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.neuropharm.2018.04.017","volume":"137","author":"EL Boshoff","year":"2018","unstructured":"Boshoff, E. L., Fletcher, E. J. R. & Duty, S. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner. Neuropharmacology 137, 156\u2013163, https:\/\/doi.org\/10.1016\/j.neuropharm.2018.04.017 (2018).","journal-title":"Neuropharmacology"},{"key":"44803_CR8","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S1474-4422(10)70254-4","volume":"9","author":"WJ Marks Jr.","year":"2010","unstructured":"Marks, W. J. Jr. et al. Gene delivery of AAV2-neurturin for Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol 9, 1164\u20131172, https:\/\/doi.org\/10.1016\/S1474-4422(10)70254-4 (2010).","journal-title":"Lancet Neurol"},{"key":"44803_CR9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"AE Lang","year":"2006","unstructured":"Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59, 459\u2013466, https:\/\/doi.org\/10.1002\/ana.20737 (2006).","journal-title":"Ann Neurol"},{"key":"44803_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.expneurol.2006.07.015","volume":"202","author":"MF Salvatore","year":"2006","unstructured":"Salvatore, M. F. et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202, 497\u2013505, https:\/\/doi.org\/10.1016\/j.expneurol.2006.07.015 (2006).","journal-title":"Exp Neurol"},{"key":"44803_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3171\/JNS-07\/07\/0074","volume":"107","author":"PF Morrison","year":"2007","unstructured":"Morrison, P. F., Lonser, R. R. & Oldfield, E. H. Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg 107, 74\u201383, https:\/\/doi.org\/10.3171\/JNS-07\/07\/0074 (2007).","journal-title":"J Neurosurg"},{"key":"44803_CR12","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1002\/mds.26426","volume":"30","author":"CW Olanow","year":"2015","unstructured":"Olanow, C. W., Bartus, R. T., Volpicelli-Daley, L. A. & Kordower, J. H. Trophic factors for Parkinson\u2019s disease: To live or let die. Mov Disord 30, 1715\u20131724, https:\/\/doi.org\/10.1002\/mds.26426 (2015).","journal-title":"Mov Disord"},{"key":"44803_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.parkreldis.2017.02.011","volume":"38","author":"SV Hegarty","year":"2017","unstructured":"Hegarty, S. V., Lee, D. J., O\u2019Keeffe, G. W. & Sullivan, A. M. Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson\u2019s disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 38, 19\u201325, https:\/\/doi.org\/10.1016\/j.parkreldis.2017.02.011 (2017).","journal-title":"Parkinsonism Relat Disord"},{"key":"44803_CR14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1080\/10717544.2018.1482972","volume":"25","author":"J Niu","year":"2018","unstructured":"Niu, J. et al. Efficient treatment of Parkinson\u2019s disease using ultrasonography-guided rhFGF20 proteoliposomes. Drug Deliv 25, 1560\u20131569, https:\/\/doi.org\/10.1080\/10717544.2018.1482972 (2018).","journal-title":"Drug Deliv"},{"key":"44803_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/exnr.1997.6415","volume":"144","author":"CD Hardman","year":"1997","unstructured":"Hardman, C. D., Halliday, G. M., McRitchie, D. A., Cartwright, H. R. & Morris, J. G. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Exp Neurol 144, 183\u2013192, https:\/\/doi.org\/10.1006\/exnr.1997.6415 (1997).","journal-title":"Exp Neurol"},{"key":"44803_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.nbd.2015.06.010","volume":"82","author":"J Tong","year":"2015","unstructured":"Tong, J. et al. Low levels of astroglial markers in Parkinson\u2019s disease: relationship to alpha-synuclein accumulation. Neurobiol Dis 82, 243\u2013253, https:\/\/doi.org\/10.1016\/j.nbd.2015.06.010 (2015).","journal-title":"Neurobiol Dis"},{"issue":"5795","key":"44803_CR17","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J. Lamb","year":"2006","unstructured":"Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929\u20131935, https:\/\/doi.org\/10.1126\/science.1132939 https:\/\/www.broadinstitute.org\/cmap\/ (2006).","journal-title":"Science"},{"key":"44803_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-765","volume":"14","author":"G Williams","year":"2013","unstructured":"Williams, G. SPIEDw: a searchable platform-independent expression database web tool. BMC Genomics 14, 765, https:\/\/doi.org\/10.1186\/1471-2164-14-765 (2013).","journal-title":"BMC Genomics"},{"key":"44803_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal, S. et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson\u2019s disease. Science 357, 891\u2013898, https:\/\/doi.org\/10.1126\/science.aaf3934 (2017).","journal-title":"Science"},{"key":"44803_CR20","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/j.1471-4159.2010.06896.x","volume":"114","author":"J Iczkiewicz","year":"2010","unstructured":"Iczkiewicz, J. et al. The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra. J Neurochem 114, 1792\u20131804, https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06896.x (2010).","journal-title":"J Neurochem"},{"key":"44803_CR21","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1111\/j.1476-5381.2012.01943.x","volume":"166","author":"MJ Betts","year":"2012","unstructured":"Betts, M. J., O\u2019Neill, M. J. & Duty, S. Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson\u2019s disease. Br J Pharmacol 166, 2317\u20132330, https:\/\/doi.org\/10.1111\/j.1476-5381.2012.01943.x (2012).","journal-title":"Br J Pharmacol"},{"issue":"1","key":"44803_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2164-13-12","volume":"13","author":"Gareth Williams","year":"2012","unstructured":"Williams, G. A searchable cross-platform gene expression database reveals connections between drug treatments and disease. BMC Genomics 13, 12, https:\/\/doi.org\/10.1186\/1471-2164-13-12 http:\/\/www.spied.org.uk\/cgi-bin\/HGNC-SPIEDXXX.cgi (2012).","journal-title":"BMC Genomics"},{"key":"44803_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.tox.2014.10.014","volume":"326","author":"I Rodger","year":"2014","unstructured":"Rodger, I. et al. Maternal rat serum concentrations of dimethadione do not explain intra-litter differences in the incidence of dimethadione-induced birth defects, including novel findings in foetal lung. Toxicology 326, 142\u2013152, https:\/\/doi.org\/10.1016\/j.tox.2014.10.014 (2014).","journal-title":"Toxicology"},{"issue":"1","key":"44803_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/0960327118769717","volume":"38","author":"O Atli","year":"2018","unstructured":"Atli, O. et al. Assessment of trazodone-induced cardiotoxicity after repeated doses in rats. Hum Exp Toxicol, 960327118769717, https:\/\/doi.org\/10.1177\/0960327118769717 (2018).","journal-title":"Human & Experimental Toxicology"},{"key":"44803_CR25","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.12.013","volume":"27","author":"Z Amtul","year":"2018","unstructured":"Amtul, Z., Haque, W. & Cechetto, D. F. Dipyridamole plus Triflusal versus Triflusal Alone in Infarct Reduction after Middle Cerebral Artery Occlusion. J Stroke Cerebrovasc Dis 27, 1283\u20131287, https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2017.12.013 (2018).","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"44803_CR26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s002040050059","volume":"68","author":"SE Libretto","year":"1994","unstructured":"Libretto, S. E. A review of the toxicology of salbutamol (albuterol). Arch Toxicol 68, 213\u2013216 (1994).","journal-title":"Arch Toxicol"},{"key":"44803_CR27","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/mds.108","volume":"33","author":"N Gronich","year":"2018","unstructured":"Gronich, N. et al. beta2-adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease. Mov Disord 33, 1465\u20131471, https:\/\/doi.org\/10.1002\/mds.108 (2018).","journal-title":"Mov Disord"},{"key":"44803_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ana.25341","volume":"84","author":"S Searles Nielsen","year":"2018","unstructured":"Searles Nielsen, S., Gross, A., Camacho-Soto, A., Willis, A. W. & Racette, B. A. Beta2-adrenoreceptor medications and risk of Parkinson disease. Ann Neurol 84, 683\u2013693, https:\/\/doi.org\/10.1002\/ana.25341 (2018).","journal-title":"Ann Neurol"},{"key":"44803_CR29","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/brain\/awx074","volume":"140","author":"M Halliday","year":"2017","unstructured":"Halliday, M. et al. Repurposed drugs targeting eIF2&alpha;-P-mediated translational repression prevent neurodegeneration in mice. Brain 140, 1768\u20131783, https:\/\/doi.org\/10.1093\/brain\/awx074 (2017).","journal-title":"Brain"},{"key":"44803_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.bbrc.2007.01.043","volume":"354","author":"JJ Hoozemans","year":"2007","unstructured":"Hoozemans, J. J. et al. Activation of the unfolded protein response in Parkinson\u2019s disease. Biochem Biophys Res Commun 354, 707\u2013711, https:\/\/doi.org\/10.1016\/j.bbrc.2007.01.043 (2007).","journal-title":"Biochem Biophys Res Commun"},{"key":"44803_CR31","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/path.3969","volume":"226","author":"DAT Nijholt","year":"2012","unstructured":"Nijholt, D. A. T., van Haastert, E. S., Rozemuller, A. J. M., Scheper, W. & Hoozemans, J. J. M. The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. J Pathol 226, 693\u2013702, https:\/\/doi.org\/10.1002\/path.3969 (2012).","journal-title":"J Pathol"},{"key":"44803_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nature11058","volume":"485","author":"JA Moreno","year":"2012","unstructured":"Moreno, J. A. et al. Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature 485, 507\u2013511, https:\/\/doi.org\/10.1038\/nature11058 (2012).","journal-title":"Nature"},{"key":"44803_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1017\/S1092852900024020","volume":"14","author":"SM Stahl","year":"2009","unstructured":"Stahl, S. M. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 14, 536\u2013546 (2009).","journal-title":"CNS Spectr"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44803-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44803-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44803-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:06:16Z","timestamp":1671271576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-44803-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["44803"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-44803-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"8336"}}